Nine senators press FDA on the 'research use only' loophole

A bipartisan group of nine senators has asked the Food and Drug Administration to explain how it polices online sellers that use “research use only” labels to sell unapproved drugs to the public. The letter, dated October 14, 2026 and addressed to Acting FDA Commissioner Kyle Diamantas, was led by Sen. Jim Banks (R-Ind.). His office posted it with a press release on October 15. The trade publications FDAnews and InsideHealthPolicy reported it on October 20.

The signed copy carries nine names: Republicans Jim Banks, Ted Budd, Tom Cotton, David McCormick, Jon Husted and Todd Young, and Democrats Martin Heinrich, Adam Schiff and Andy Kim. We read the full two-page letter.

What the letter says

The senators argue that the research label has become a way around FDA oversight. Products sold that way, they write, are not made under current good manufacturing practice and are not subject to quality-control or stability testing, which leaves them open to “contamination, impurity, mislabeling, and misuse.”

Their main example is retatrutide, Eli Lilly’s experimental obesity drug, which is still in Phase 3 trials and has not been approved. The letter says many online vendors already sell it, often made from active ingredients sourced from unregulated manufacturers in China. It cites America’s Poison Centers figures showing a 265% increase in poisonings linked to illicit retatrutide in the first four months of 2026 compared with the last four months of 2025.

The letter credits FDA’s enforcement so far. It says the agency has sent warning letters to at least seven companies for selling retatrutide “for research use only” while promoting it for obesity, diabetes and other human uses, and to more than a dozen others over unapproved retatrutide. But it says warning letters alone are not stopping the trade. The senators want FDA to work more closely with U.S. Customs and Border Protection and other law enforcement agencies, writing that “Stronger security at ports of entry, more investigations of affiliated companies, and prosecutions are badly needed.”

They ask for a briefing covering three things: FDA’s own assessment of how widely the research label is used and misused; how it coordinates with Customs and with federal, state and local police to stop illicit drugs and ingredients at the border; and whether it has the capacity to investigate and act against vendors who break the law.

Why it matters

Congressional letters do not change the law, and this one sets no deadline. Its weight is in who signed it. Six Republicans and three Democrats agreeing that the research label is a “dangerous loophole” puts pressure on FDA from a direction separate from the administration’s current push to widen legal access to some peptides through pharmacies.

The two tracks are different. The interim access policy now under White House review, as reported, would cover licensed pharmacies filling prescriptions. The senators’ letter is about the unlicensed online market, where sellers disclaim human use on the label while marketing for it elsewhere. FDA’s warning letters have long treated that marketing as evidence of what a product is really for, as our explainer sets out, but a warning letter is a notice, not a seizure or a prosecution.

InsideHealthPolicy linked the letter to recent reports of deaths. CBS News reported on October 13 that FDA’s adverse event system had received two reports of people who died after using products claiming to be retatrutide. CBS said the reports are unverified and do not establish that the products caused either death. The senators’ letter itself does not mention those reports.

What is not known

• Whether FDA has agreed to brief the senators, or when.
• The underlying poison-center data. The letter cites the percentage change but not the counts, and we have not seen the dataset it draws on.
• Whether any joint FDA and Customs action is planned. Neither agency has announced one.

What to watch

Any FDA reply or briefing; new warning letters to retatrutide sellers, which FDA posts weekly; import alerts covering peptide ingredients; and Lilly’s own lawsuits against sellers, which we track in our court coverage.